
Assessing Viral Clearance in Early-Phase Process Development

mAb Purification Process Development Using Mixed-Mode Resins — The DOE Approach

A Rapid, Culture-Free Method to Determine 50% Neutralization Titer (NT50) Using the ACE2-Competitive Bio-Plex Pro SARS-CoV-2 Neutralization Antibody Assay

Flow Cytometry Empowers CAR T-Cell Therapies

Scalable Purification Strategies for Viral Vectors and Vaccines

Maximizing Metastasis Insights with a Novel Integrated Workflow for CTC Enrichment and Enumeration

Generating Anti-CD19 CAR T Cells with High Efficiency and Viability via mRNA Electroporation

Downstream Process Development for the Purification of Biosimilar Insulin from Escherichia coli

What You Need to Know About Packing Resins at Process Scale
